Lowenstein senior counsel James C. Shehan, Chair, FDA Regulatory practice, and member of the firm's Life Sciences practice, participates in this online panel as part of BIO's 2020 International Convention, BIO Digital.
BIO Digital is a virtual gathering of the global biotech industry and provides access to key partners via BIO One-on-One Partnering, educational resources to help drive business, and the insights needed to continue critical research and development.
Program description:
The promise of gene and cell therapies, advances in genetic screening and related diagnostics, and precision medicine has generated widespread enthusiasm throughout the rare disease community. At the same time, new patient-focused drug development is giving patient groups a pathway to new treatments. Yet, despite advances, 95% of rare diseases still do not have a treatment.
With Congress considering ways to update the 21st Century Cures Act and new studies imagining future scenarios, this session will explore new approaches to incentives and patient collaboration to foster a new era in orphan drug development for the 30 million Americans suffering with a rare disease.
Moderator: Natasha Bonhomme, Chief Strategy Officer, Genetic Alliance
Panelists:
- James C. Shehan, Senior Counsel; Chair, FDA Regulatory; member, Life Sciences, Lowenstein Sandler LLP
- Laura Clague, Chief Financial Officer, Retrophin
- Nick Leschly, President & CEO, bluebird bio
- Bonnie Schneider, Founder & Director, IGA Nephropathy Foundation of America
Time: 4:30 p.m.-5:25 p.m. Pacific Time
